We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03285477
Recruitment Status : Completed
First Posted : September 18, 2017
Results First Posted : March 10, 2021
Last Update Posted : April 13, 2021
Sponsor:
Collaborator:
Athenex, Inc.
Information provided by (Responsible Party):
Almirall, S.A.

Brief Summary:
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face or scalp.

Condition or disease Intervention/treatment Phase
Actinic Keratoses Drug: Placebo Drug: KX2-391 Ointment 1% Phase 3

Detailed Description:

This study was a double-blinded, multicenter, activity, and safety study of KX2-391 Ointment administered topically to the face or scalp of participants with actinic keratosis.

The study consists of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods. Eligible participants received 5 consecutive days of topical treatment, to be applied at the study site. Activity (lesion counts) and safety evaluations was performed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 351 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This study tested KX2-391 Ointment 1% against a placebo.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: All Central Vendors and the sponsor were masked. The sponsor was unblind at the end of Day 57.
Primary Purpose: Treatment
Official Title: A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp
Actual Study Start Date : September 18, 2017
Actual Primary Completion Date : May 3, 2018
Actual Study Completion Date : April 24, 2019

Arm Intervention/treatment
Placebo Comparator: Placebo
Vehicle Ointment was applied topically once daily for 5 consecutive days on face or scalp
Drug: Placebo
Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.

Experimental: KX2-391 Ointment 1%
KX2-391 Ointment 1% was applied topically once daily for 5 consecutive days on face or scalp
Drug: KX2-391 Ointment 1%
The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.




Primary Outcome Measures :
  1. Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions [ Time Frame: Day 57 ]
    Complete clearance rate was defined as the percentage of participants at Day 57 with no clinically visible AK lesions in the treatment area.


Secondary Outcome Measures :
  1. Percentage of Participants With Partial Clearance Rate of Actinic Keratosis Lesions at Day 57 [ Time Frame: Day 57 ]
    Partial clearance rate of AK lesions was defined as the percentage of participants with a greater than or equal to (>=) 75% reduction in the number of AK lesions identified at Baseline (Day 1 predose) in the treatment area.

  2. Overall Change From Baseline in Actinic Keratosis Lesion Counts at Days 8, 15, 29 and 57 [ Time Frame: Days 8, 15, 29 and 57 ]
    Overall the change from baseline in lesion count at each visit were summarized and reported using descriptive statistics by treatment location (face or scalp).

  3. Percentage of Participants With Recurrence of Actinic Keratosis Lesions Who Achieved Complete Clearance at Day 57 [ Time Frame: 3, 6, 9 and 12 months post-Day 57 ]
    Recurrence rate was estimated based on Kaplan-Meier method, with recurrence define as appearance of any AK lesions in the treatment area, including those recurred or newly identified.

  4. Number of Participants With Maximal Post Baseline Local Skin Reaction (LSR) [ Time Frame: Day 57 ]
    Maximal post baseline LSR was defined as the highest grade of any LSR reported at any post baseline visits for a participant. The LSR assessment was an Investigator's (or sub-investigator's) assessment of the following signs on the treatment area: erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. The LSRs were graded on a 4-point scale ranging from 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense).

  5. Number of Participants With Pigmentation and Scarring in the Treatment Area [ Time Frame: Baseline (Day 1 predose), Days 5, 8, 15, 29 and 57 ]
    Absence or presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment area were assessed.

  6. Number of Participants With Adverse Event (AE), Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Events of Special Interests [ Time Frame: Baseline (Day 1 predose) up to Day 57 ]
    An AE was defined as any untoward medical occurrence in participant which does not necessarily have causal relationship with treatment. An AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal product, whether or not considered related to medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death; was life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in patient hospitalization; was congenital anomaly/birth defect or otherwise considered medically important. TEAEs (serious and non-serious) were defined as either those AEs with onset after first dose or those pre-existing AEs that worsen after first dose. Events of special interest included skin cancers (including basal cell carcinoma, squamous cell carcinoma, melanoma and their location and treatment area), ocular exposure, overdose, and pregnancy.

  7. Number of Participants With Adverse Events, Serious Adverse Events, Events of Special Interests Within the Treatment Area After Day 57 and up to 12 Months Post-Day 57 [ Time Frame: From Day 57 up to 12-months post-Day 57 ]
    An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death; was life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in patient hospitalization; was congenital anomaly/birth defect or otherwise considered medically important. Events of special interest included skin cancers (including basal cell carcinoma, squamous cell carcinoma, melanoma and their location and treatment area), ocular exposure, overdose, and pregnancy.

  8. Number of Participants With Clinically Significant Safety Observations- Hematology, Blood Chemistry, Urinalysis [ Time Frame: From Baseline (Day 1 predose) up to Day 57 ]
    Assessed laboratory parameters included hematology, blood chemistry and urinalysis. Clinical significance and abnormal observations were determined by the investigator.

  9. Number of Participants With Clinically Significant Safety Observations- Vital Signs [ Time Frame: From Baseline (Day 1 predose) up to Day 57 ]
    Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinical significance was determined by the investigator.

  10. Number of Participants With Clinically Significant Safety Observations- Physical Examination [ Time Frame: From Baseline (Day 1 predose) up to Day 57 ]
    A physical examination included weight and height measurements was performed. Clinical significance was determined by the investigator.

  11. Number of Participants With Clinically Significant Safety Observations- Electrocardiograms (ECGs) [ Time Frame: From Baseline (Day 1 predose) up to Day 57 ]
    ECG parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals. Clinical significance was determined by the investigator.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Males and females greater than or equal to (≥) 18 years old
  2. A defined area on the face or scalp contains 4 to 8 clinically typical, visible, and discrete AK lesions
  3. Participants who in the judgment of the Investigator, are in good general health
  4. Females must be postmenopausal [greater than (>) 45 years of age with at least 12 months of amenorrhea], surgically sterile (by hysterectomy, bilateral oophorectomy, or tubal ligation); or, if of childbearing potential, must be using highly effective contraception for at least 30 days or 1 menstrual cycle, whichever is longer, prior to study treatment and must agree to continue to use highly effective contraception for at least 30 days following their last dose of study treatment. Highly effective contraception includes oral hormonal contraceptives, hormonal contraceptive implant, injection or patch, intrauterine device or complete abstinence from sexual intercourse.
  5. Sexually active males who have not had a vasectomy, and whose partner is reproductively capable, must agree to use barrier contraception from Screening through 90 days after their last dose of study treatment.
  6. All participants must agree not to donate sperm or eggs or attempt conception from Screening through 90 days following their last dose of study treatment
  7. Willing to avoid excessive sun or UV exposure
  8. Able to comprehend and are willing to sign the informed consent form (ICF).

Exclusion Criteria

  1. Clinically atypical and/or rapidly changing AK lesions on the treatment area
  2. Location of the selected area is:

    • On any location other than the face or scalp
    • Within 5 cm of an incompletely healed wound
    • Within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)
  3. Been previously treated with KX2-391 Ointment
  4. Anticipated need for in-patient hospitalization or in-patient surgery from Day 1 to Day 57
  5. Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for AK within the treatment area or within 2 cm of the treatment area, within 8 weeks prior to the Screening visit
  6. Use of the following therapies and/or medications within 2 weeks prior to the Screening visit:

    • Cosmetic or therapeutic procedures (eg, use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing) within the treatment area or within 2 cm of the selected treatment area
    • Acid-containing therapeutic products (eg, salicylic acid or fruit acids, such as alpha- and beta-hydroxyl acids and glycolic acids), topical retinoids, or light chemical peels within the treatment area or within 2 cm of the selected treatment area
    • Topical salves (non-medicated/non-irritant lotion and cream are acceptable) or topical steroids within the treatment area or within 2 cm of the selected treatment area; artificial tanners within the treatment area or within 5 cm of the selected treatment area
  7. Use of the following therapies and/or medications within 4 weeks prior to the Screening visit:

    • Treatment with immunomodulators (eg, azathioprine), cytotoxic drugs (eg, cyclophosphamide, vinblastine, chlorambucil, methotrexate) or interferons/interferon inducers
    • Treatment with systemic medications that suppress the immune system (eg, cyclosporine, prednisone, methotrexate, alefacept, infliximab)
  8. Use of systemic retinoids (eg, isotretinoin, acitretin, bexarotene) within 6 months prior to the Screening visit
  9. A history of sensitivity and/or allergy to any of the ingredients in the study medication
  10. A skin disease (eg, atopic dermatitis, psoriasis, eczema) or condition (eg, scarring, open wounds) that, in the opinion of the Investigator, might interfere with the study conduct or evaluations, or which exposes the participants to unacceptable risk by study participation
  11. Other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the Investigator, would expose the participant to unacceptable risk by study participation
  12. Females who are pregnant or nursing
  13. Participated in an investigational drug trial during which an investigational study medication was administered within 30 days or 5 half-lives of the investigational product, whichever is longer, before dosing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03285477


Locations
Show Show 30 study locations
Sponsors and Collaborators
Almirall, S.A.
Athenex, Inc.
Investigators
Layout table for investigator information
Study Chair: Jane Fang, MD Athenex, Inc.
  Study Documents (Full-Text)

Documents provided by Almirall, S.A.:
Study Protocol  [PDF] February 18, 2018
Statistical Analysis Plan  [PDF] June 4, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Almirall, S.A.
ClinicalTrials.gov Identifier: NCT03285477    
Other Study ID Numbers: KX01-AK-003
U1111-1191-8233 ( Other Identifier: UTN )
First Posted: September 18, 2017    Key Record Dates
Results First Posted: March 10, 2021
Last Update Posted: April 13, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Almirall, S.A.:
Actinic Keratosis
Keratosis
Keratosis, Actinic
Skin Diseases
Actinic Keratoses
Precancerous Conditions
Neoplasms
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratosis, Actinic
Keratosis
Skin Diseases
Precancerous Conditions
Neoplasms
Tirbanibulin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action